Background and aimResveratrol shows remarkable anti-inflammatory activities in experimental models. This study aims to evaluate the effect of resveratrol, as an adjuvant with meloxicam (Mlx), on the pain and functional activity during a 90-day period and monitor the adverse effects on kidney and liver functions, lipid profile, and hematological markers.Patients and methodsThis study was a double-blind, placebo-controlled, randomized multi-center study that involved 110 patients with knee osteoarthritis (OA) and was performed at Sulaimani City, Iraq, from December 2016 to September 2017. To assess the effects of Mlx with or without resveratrol, pain severity and functional disability were evaluated at baseline and after 90 days using the Western Ontario and McMaster Universities Osteoarthritis Index. Fasting blood was collected to evaluate the lipid profile markers, hematological picture, and liver and kidney functions, in addition to vitamin D level.ResultsResveratrol significantly improves pain, functions, and associated symptoms compared with placebo. The clinical and biochemical markers indicated that 500 mg/day of resveratrol, as an adjuvant with Mlx, is safe and well tolerated by the knee OA patients.ConclusionResveratrol, as an “add-on” medication with Mlx, was superior in terms of safety and efficacy to Mlx alone for the treatment of pain and improvement of physical function in patients with knee OA.

Resveratrol, a polyphenolic compound, is a powerful antioxidant with remarkable anti-inflammatory properties. Inflammation and pain plays an important role in the pathogenesis of knee osteoarthritis (OA) and could cause tissue damage and morbidity. The aim of this study was to evaluate the anti-inflammatory and pain reduction activities of orally administered resveratrol in patients with knee OA. We carried out a 90-day pilot study to evaluate the ability of orally administered resveratrol, as an adjuvant with meloxicam, to decrease knee joint pain and biomarkers of inflammation in comparison with a placebo. One hundred ten men and women (45-75 years old) diagnosed with mild to moderate knee OA were treated with 15 mg per day meloxicam and either 500 mg per day resveratrol or placebo for 90 days in a double-blind, randomized control trial. Pain severity was evaluated at the beginning and at the end of treatment using Visual Analogue Scale-100 scores. Fasting blood was collected to determine serum interleukins 1β and 6, tumor necrosis factor-α, C-reactive protein, and complement proteins C3 and C4. The resveratrol-treated group experienced a time-dependent significant decrease in pain severity (P < .001). Serum levels of the biochemical markers were significantly reduced compared with the placebo-treated group (P < .01). These findings suggest that resveratrol may be an effective "add-on" option with meloxicam in the treatment of patients with mild to moderate knee OA.

The present study aimed to evaluate the effect of the adjuvant use of resveratrol with meloxicam on the clinical scores of knee OA patients. This was a double-blind placebo-controlled randomised trial involving 100 patients with knee osteoarthritis performed at the

No abstract

Background and objectives: Anterior cruciate ligament reconstruction is one of the most common knee operations. The graft fixation ways differ from suspensory fixation methods (Endobutton) to aperture fixation (Interference screws). The use of a hamstring tendon autograft has become a common choice among orthopedic surgeons because of less donor site problem. The aim of this study is to compare the functional outcome between suspensory fixation and aperture fixation of arthroscopic anterior cruciate ligament reconstruction. Methods: Arthroscopic autogenous hamstring anterior cruciate ligament reconstruction was performed for forty-one patients who were divided into two groups, with a minimum of six months follow-up evaluation. The suspensory fixation group underwent endobutton fixation on the femoral side and interference screw on tibial side. The aperture fixation group underwent interference screw fixation at both femoral and tibial tunnels. Both groups were assessed and their functional outcomes were compared before surgery, at three months and six months by using Lysholm knee score. Results: There was significant improvement in functional outcome in both groups, at six months of follow-up, the Lysholm score in endobutton group improved from 77.2 to 93.2 and in interference screw group from 71.5 to 89. The endobutton group had better functional outcome when compared to interference screw group. Conclusions: The endobutton fixation provided better functional outcome at the end of six months when comparing the result. We recommend larger population and longer periods of follow-up.